Dr. Karlan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
100 UCLA Medical Plaza, Suite 383
Los Angeles, CA 90095Phone+1 310-794-7274Fax+1 310-794-7436
Summary
- Beth Y. Karlan, M.D. is Professor and Vice Chair of Women’s Health Research in the Department of Obstetrics and Gynecology at the David Geffen School of Medicine, University of California Los Angeles (UCLA). She is also Director of Cancer Population Genetics at the Jonsson Comprehensive Cancer Center at UCLA. Dr. Karlan’s research focuses on ovarian and other women’s cancers as well as inherited cancer susceptibility. She has authored over 350 research publications and is an American Cancer Society Clinical Research Professor. Dr. Karlan is Editor-in-Chief of the scientific journals Gynecologic Oncology and Gynecologic Oncology Reports, and is a Fellow of the American Society of Clinical Oncology. In 2012, Dr. Karlan was appointed by the White House to serve on the National Cancer Advisory Board, and in 2015 she was elected to membership in the National Academy of Medicine.
Education & Training
- Yale-New Haven Medical CenterResidency, Obstetrics and Gynecology, 1982 - 1986
- Harvard Medical SchoolClass of 1982
- Harvard-Radcliffe CollegeB.A., Biochemical Sciences, Magna Cum Laude, 1978
Certifications & Licensure
- CA State Medical License 1986 - 2026
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Lifetime Achievement Award International Gynecologic Cancer Society, 2021
- Giants of Cancer Care, Gynecologic Malignancies OncLive, 2019
- Director's Service Award National Cancer Institute, 2018
- Join now to see all
Clinical Trials
- A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women Start of enrollment: 2009 Nov 01
Publications & Presentations
PubMed
- The incidence of pancreatic cancer in women with a BRCA1 or BRCA2 mutation.Bryson W Katona, Jan Lubinski, Tuya Pal, Tomasz Huzarski, William D Foulkes
Cancer. 2024-11-29 - Medicaid Coverage of NCCN- and ASCO/SSO-Guideline-Concordant BRCA Germline Testing for Patients with Breast Cancer: Opportunity to Embrace Rapid Advancements in Precis...Hattie H Huston-Paterson, Vanessa Mora, Beth Y Karlan, Mediget Teshome
Annals of Surgical Oncology. 2024-11-23 - Incidence of peritoneal cancer after oophorectomy among BRCA1 and BRCA2 mutation carriers.Steven A Narod, Jacek Gronwald, Beth Karlan, Pal Moller, Tomasz Huzarski
Journal of the National Cancer Institute. 2024-11-01
Journal Articles
- Association of p16 Expression with Prognosis Varies Across Ovarian Carcinoma Histotypes: An Ovarian Tumor Tissue Analysis Consortium StudyRobert P Edwards, Beth Y Karlan, Andrew Berchuck, The Journal of Pathology: Clinical Research
- Variants in Genes Encoding Small GTPases and Association with Epithelial Ovarian Cancer SusceptibilityJulie M Cunningham, Robert P Edwards, Elizabeth M Poole, Tanja Pejovic, Karen Lu, Kunle Odunsi, Beth Y Karlan, Christine S Walsh, Douglas A Levine, Andrew Berchuck, Da..., PLoS One
- Functional Mechanisms Underlying Pleiotropic Risk Alleles at the 19p13.1 Breast–Ovarian Cancer Susceptibility LocusSusan M Domchek, Beth Y Karlan, Katherine L Nathanson, Kenneth Offit, Banu K Arun, Andrew Berchuck, Patricia A Ganz, Douglas A Levine, Nature
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Morbidity of triplemodality therapy in the management of early stage cervical cancer.Park SK, Axtell AE, Hakimian B, Li A, Leuchter R, Karlan B, Rimel BJ, Walsh C, Cass I, Western Association of Gynecologic Oncologists Meeting, Truckee, CA, 6/25/2014
- A KRAS hotspot mutation correlates with MLH1 methylation in endometrial carcinomas with microsatellite instability: A potential triage tool for Lynch Syndrome evaluation.Cohen J, Wiedemeyer R, Karlan B, Walsh C, Society of Gynecologic Oncology 45th Annual Meeting on Women's Cancer, Tampa, FL, 3/22/2014
- Genomic characterization of grade 3 endometrial carcinoma.Cohen J, Goodman M, Karlan B and Walsh C, Society of Gynecologic Oncology 45th Annual Meeting on Women's Cancer, Tampa, FL, 3/22/2014
- Join now to see all
Lectures
- The prognostic significance of ADAM metallopeptidase domain 12 in advanced stage serous ovarian cancer.Truckee, CA - 6/25/2014
- Occult and subsequent gynecologic cancers following risk-reducing salpingo-oophorectomies (RRSO) in BRCA mutation carriers.Truckee, CA - 6/25/2014
- "The Mechanics of Writing and Publishing Great Papers: Perspecitive from the Editor-in-Chief of Gynecologic Oncology", Inaugural LecturerUniversity of Alabama, Birmingham, AL - 11/15/2013
- Join now to see all
Other
- "Interview for Lifescript.com"Beth Young Karlan, MD
1/1/2013 - "Interview for Studio 11"Beth Young Karlan, MD
1/1/2013 - CA-125: To monitor or not to monitor?Rustin G, Karlan BY and Markman M
http://www.medscape.com
3/8/2012 - Join now to see all
Authored Content
- Disappointing but Important: Cervical Cancer OUTBACK Trial’s Negative ResultsJune 2021
Press Mentions
- Researchers Finds How the Ovarian Cancer Can Develop in WomenJanuary 3rd, 2022
- Health News | Research Explains How Ovarian Cancer Begins in High-Risk WomenJanuary 2nd, 2022
- Human iPSC-Derived Fallopian Tube Organoids Reveal the Origins of Common Ovarian CancerDecember 29th, 2021
- Join now to see all
Professional Memberships
- Fellow
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: